Navigation Links
KV Pharmaceutical Divests ANDA for Generic Version of Duac(R)
Date:9/21/2009

ST. LOUIS, Sept. 21 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) today announced the sale to Perrigo Company (Nasdaq: PRGO) of KV's first-to-file Paragraph IV Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for a generic equivalent version of GlaxoSmithKline's Duac(R) gel.

Under the terms of the transaction, KV will receive $14 million from Perrigo at closing and an additional, $2 million milestone payment upon the completion of a successful technical transfer. Duac(R) (clindamycin, 1%-benzoyl peroxide, 5%) is indicated for the topical treatment of mild to moderate acne vulgaris.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a subsidiary that competes with branded products, and Ther-Rx Corporation, the company's branded drug subsidiary.

For further information about KV Pharmaceutical Company, please visit the Company's corporate Web site at www.kvpharmaceutical.com.

Cautionary Note Regarding Forward-looking Statements

The information in this press release may contain various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning the operations, future results and prospects of the Company. Such statements may be identified by the use of words like "plan," "expect," "aim," "b
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Vestara and MedClean Technologies Announce Co-Marketing Partnership to Expand Innovative Solution for Pharmaceutical Waste Management
2. VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ
3. Valeant Pharmaceuticals to Present at the UBS Global Life Sciences Conference
4. Siperian to Host Webinar With Panel of Pharmaceutical Experts
5. Glaxo Official Memo Urged Scientists to Withhold Information About Paxils Risks, Trial Hears; Pharmaceutical Industry Today Offers Complete News Coverage
6. Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
7. AUDIO from Medialink and Solvay Pharmaceuticals: New High Five Program Addresses Energy Levels of Overweight Men
8. KV Pharmaceutical Receives Stockholder Action by Written Consent
9. Caraco Pharmaceutical Laboratories, Ltd. Announces Appointment of F. Folsom Bell to Board of Directors
10. UK's Newcastle University Introduces First-Ever Biopharmaceutical Engineering Doctorate Program
11. Sun Pharmaceutical Announces Expiration of HSR Act Waiting Period for Taro Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... professor in the new Institute for Biomedical Sciences ... $2.83 million federal grant to develop novel therapeutics ... grant from the Eunice Kennedy Shriver National Institute ... National Institutes of Health will support Plemper,s drug ... at least one distinct alternative compound. , Infections ...
(Date:4/24/2014)... to give than to receive at least if you,re ... , The study found that 15- and 16-year-olds who find ... family members, are less likely to become depressed than those ... the money for themselves. , The researchers detail their findings ... . , The study focused on the ventral striatum, a ...
(Date:4/24/2014)... pH1N1 virus caused the first flu pandemic in the ... and killed more than 50 people in the country. ... flu epidemics (winter/spring seasons). , Infections with influenza ... World Health Organization has recommended Tamiflu for treatment of ... this drug is that it targets viral proteins which ...
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
(Date:4/23/2014)... to high-energy particles, simulating conditions astronauts would face on ... and slower reaction times, even when the radiation exposure ... impairments which affected a large subset, but far ... linked to protein changes in the brain, the scientists ... humans, suggest it may be possible to develop a ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... in the cereal category as they provide fibre beta glucan ... health-conscious consumers. So there is news to cheer now as ... called beta-glucan in their diets.,This variety of oats has been ... University (NDSU) scientists., ,Beta-glucan can help lower blood levels ...
... A new study has found that at high doses, ... result in liver damage, leading to significant health risks. ... University of Toronto, results of which can be found ... ,Previous studies have demonstrated the anti-oxidant effects of ...
... found out that retinal examination of a child, to determine the ... of abuse. // This was discussed in the American Academy of ... is a light sensitive tissue located behind the eye. Any rupture ... the result is bleeding or retinal hemorrhage. , A ...
... a molecular computer, which uses enzymes to perform calculations ... release of drugs.// ,Itamar Willner, who built ... Jerusalem in Israel, said the enzyme-powered computers could have ... future, be implanted into humans. ,The researchers ...
... California was slapped with four additional law suits, after the ... miserably. // ,Orange county Superior court has ... of patients who died just waiting for the transplants; the ... ,The liver transplant program transparent to gross mismanagement has to ...
... of doctors at the U.S. military prison in Guantanamo ... strike) through insertion of feeding tubes // through their ... who claim that such practices violate the fundamental principles ... are being subjected to harsh interrogations, targeted at extension ...
Cached Medicine News:Health News:Retinal Hemorrhage: No More a Sure Sign of Child Abuse 2Health News:Medical Ethics Violated By Prison Officials In Guantanamo Bay 2
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
The INSIGNIA® pacing systems allow the physician to provide customized adaptive-rate pacing therapy to meet individual patient needs....
... less than thirty pounds, the EUB 405 ... quality. Compatible with a wide range of ... solution for a variety of clinical settings. ... easy to operate. It includes an alphanumeric ...
... The HI VISION 6500 ... offers advanced clinical imaging, enhanced ... flexibility, all in robust and ... a better clinical solution in ...
... The PENTAX FG-36UX provides a wide range ... It is also possible to obtain a clear ... Flow Mapping and Color Flow Angio. An accessory ... has improved. Those feature make it possible for ...
Medicine Products: